-transparent.png){kind=logo}
The nirmatrelvir-ritonavir (Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022. Administered orally, it is intended only for people at very high risk of contracting one or more severe forms of the disease.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
June 2023,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
January 2022,
WMJ : official publication of the State Medical Society of Wisconsin,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
January 2023,
Therapie,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
February 2022,
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
September 2023,
The Medical journal of Malaysia,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
May 2023,
Obstetrics and gynecology,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
February 2023,
Journal of medical virology,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
April 2022,
Australian prescriber,
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
April 2023,
Pediatric nephrology (Berlin, Germany),
Jacques Buxeraud, and
Sébastien Faure, and
Édouard Fougere
October 2022,
Clinical pharmacology and therapeutics,
